THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 24 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $9,526,000 | -0.2% | 9,790,000 | -1.0% | 0.02% | -11.8% |
Q1 2020 | $9,543,000 | +28.0% | 9,890,000 | +31.9% | 0.02% | +30.8% |
Q2 2018 | $7,453,000 | -36.3% | 7,500,000 | -34.8% | 0.01% | -35.0% |
Q1 2018 | $11,693,000 | -14.7% | 11,500,000 | -8.0% | 0.02% | -13.0% |
Q4 2017 | $13,710,000 | -10.8% | 12,500,000 | 0.0% | 0.02% | -17.9% |
Q3 2017 | $15,367,000 | -9.2% | 12,500,000 | 0.0% | 0.03% | -12.5% |
Q2 2017 | $16,929,000 | – | 12,500,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
LINDEN ADVISORS LP | 71,957,000 | $88,374,000 | 3.14% |
Context Capital Management, LLC | 3,500,000 | $4,288,000 | 2.87% |
Mohican Financial Management, LLC | 1,000,000 | $1,250,000 | 2.40% |
Verition Fund Management LLC | 8,000,000 | $9,835,000 | 0.79% |
ZAZOVE ASSOCIATES LLC | 8,170,000 | $10,024,000 | 0.51% |
Baupost Group | 30,000,000 | $37,125,000 | 0.46% |
WOLVERINE ASSET MANAGEMENT LLC | 24,020,000 | $29,431,000 | 0.33% |
SSI INVESTMENT MANAGEMENT LLC | 3,007,000 | $3,683,000 | 0.31% |
CSS LLC/IL | 2,900,000 | $3,556,000 | 0.17% |
Rock Springs Capital Management LP | 1,500,000 | $1,844,000 | 0.08% |